@conference {143703,
	title = {Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) {\textpm} capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer (mB},
	booktitle = {San Antonio Breast Cancer Symposium},
	year = {2014},
	month = {2014},
	address = {Texas}
}
